{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:59:53Z","timestamp":1781020793213,"version":"3.54.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This systematic review summarizes the evidence informing 2 recommendations from the updated American Society of Hematology guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, comparing conventional induction and postremission therapy vs hypomethylating agents (HMA)- or low-dose cytarabine (LDAC)-based strategies, with or without venetoclax. We searched Ovid MEDLINE and Embase, and Cochrane CENTRAL through February 2024, and monitored these databases for new studies throughout November 2024. We included randomized controlled trials (RCTs) and nonrandomized studies (NRS). Reviewers screened studies, extracted data, assessed risk of bias, conducted random-effects meta-analyses, and rated certainty of evidence using GRADE (grading of recommendations, assessment, development, and evaluation). We included 21 studies (3 RCTs, 18 NRS). Compared with HMA- or LDAC-based monotherapy, conventional 7+3-type remission induction therapy may reduce mortality at longest follow-up (risk ratio [RR], 0.94; 95% confidence interval [CI], 0.85-1.04; low certainty), increase complete remission rates (odds ratio, 1.75; 95% CI, 1.25-2.38; high certainty), and may reduce recurrence at longest follow-up (RR, 0.81; 95% CI, 0.64-1.04; low certainty). Conventional therapies probably increase most severe toxicities (moderate certainty). Compared with HMA or LDAC combined with venetoclax, very low certainty evidence suggests that conventional therapy may reduce 1-year mortality (RR, 0.72; 95% CI, 0.60-0.87), increase allogeneic transplant rates (RR, 2.28; 95% CI, 1.70-3.06), result in no important differences in complete remission or recurrence, and have variable effects on severe toxicities. Conventional therapy may have benefits over HMA or LDAC alone; however, compared with HMA or LDAC plus venetoclax, the evidence remains of very low certainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016877","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:55:56Z","timestamp":1770839756000},"page":"4067-4081","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Conventional therapy vs HMA or LDAC with or without venetoclax in older adults with AML: systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-6171","authenticated-orcid":false,"given":"Sara","family":"Ibrahim","sequence":"first","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-5491","authenticated-orcid":false,"given":"Barbara","family":"Burgos-Mansilla","sequence":"additional","affiliation":[{"name":"2Departamento de Ciencias de la Rehabilitaci\u00f3n, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4564-5973","authenticated-orcid":false,"given":"Yetiani","family":"Roldan","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6844","authenticated-orcid":false,"given":"Maria Jose","family":"Oliveros","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"2Departamento de Ciencias de la Rehabilitaci\u00f3n, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6399-936X","authenticated-orcid":false,"given":"Gurleen","family":"Bhogal","sequence":"additional","affiliation":[{"name":"3Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-3975","authenticated-orcid":false,"given":"Gonzalo","family":"Bravo-Soto","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"4Michael G. DeGroote National Pain Center, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3369-4948","authenticated-orcid":false,"given":"Mobina","family":"Bagherianlemraski","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Movahed","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvistay","family":"Gutierrez-Arias","sequence":"additional","affiliation":[{"name":"5Departamento de Apoyo en Rehabilitaci\u00f3n Cardiopulmonar Integral, Instituto Nacional del T\u00f3rax, Santiago, Chile"},{"name":"6INTRehab Research Group, Exercise and Rehabilitation Sciences Institute, Universidad Andres Bello, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8425-6117","authenticated-orcid":false,"given":"Francesca","family":"Mulazzani","sequence":"additional","affiliation":[{"name":"7Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanin","family":"Khorrami Taj","sequence":"additional","affiliation":[{"name":"8School of Interdisciplinary Science, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-971X","authenticated-orcid":false,"given":"Seyed Kaveh","family":"Hadeiy","sequence":"additional","affiliation":[{"name":"9Emergency Department, Bahari Hospital, Hamedan University of Medical Sciences, Hamedan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1302-7927","authenticated-orcid":false,"given":"Manahil","family":"Qureshi","sequence":"additional","affiliation":[{"name":"15School of Earth, Environment & Society, Faculty of Science, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifur R.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-2845","authenticated-orcid":false,"given":"Rachel","family":"Couban","sequence":"additional","affiliation":[{"name":"3Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"10City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Fletcher","sequence":"additional","affiliation":[{"name":"11Willamette Valley Cancer Institute, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gilberto","sequence":"additional","affiliation":[{"name":"12Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mattison","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"14Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-9900","authenticated-orcid":false,"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[{"name":"1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"3","key":"2026060911214405500_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2026060911214405500_bib2","doi-asserted-by":"crossref","first-page":"e0278578","DOI":"10.1371\/journal.pone.0278578","article-title":"Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: a systematic review","volume":"17","author":"Hao","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"2026060911214405500_bib3","doi-asserted-by":"crossref","first-page":"e0249087","DOI":"10.1371\/journal.pone.0249087","article-title":"Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: a systematic review","volume":"16","author":"Chang","year":"2021","journal-title":"PLoS ONE"},{"issue":"13","key":"2026060911214405500_bib4","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"28","key":"2026060911214405500_bib5","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.21.00960","article-title":"When less is more: reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era","volume":"39","author":"Short","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026060911214405500_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3324\/haematol.2022.280803","article-title":"Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges","volume":"108","author":"Schlenk","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"2026060911214405500_bib7","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"24","key":"2026060911214405500_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2026060911214405500_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060911214405500_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2026060911214405500_bib11","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.bneo.2024.100016","article-title":"Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia","volume":"1","author":"Madarang","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"8","key":"2026060911214405500_bib12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"issue":"15","key":"2026060911214405500_bib13","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2026060911214405500_bib14","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1182\/bloodadvances.2023009696","article-title":"Updating the American Society of Hematology guidelines for treating older adults with acute myeloid leukemia","volume":"7","author":"Stone","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2026060911214405500_bib15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2026","journal-title":"Blood Adv"},{"issue":"10","key":"2026060911214405500_bib16","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/bloodadvances.2020001768","article-title":"Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences","volume":"4","author":"Wiercioch","year":"2020","journal-title":"Blood Adv"},{"key":"2026060911214405500_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"22","key":"2026060911214405500_bib18","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.3390\/cancers15225409","article-title":"Treatment of acute myeloid leukemia in older adults","volume":"15","author":"Alsouqi","year":"2023","journal-title":"Cancers"},{"key":"2026060911214405500_bib19","unstructured":"Evidence Prime [Software]. Laser AI. 2024. Accessed 17 February 2026. https:\/\/laser.ai."},{"key":"2026060911214405500_bib20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026060911214405500_bib21","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"2026060911214405500_bib22","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2026060911214405500_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"32","key":"2026060911214405500_bib24","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"issue":"7650","key":"2026060911214405500_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026060911214405500_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2026060911214405500_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2026060911214405500_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2026060911214405500_bib29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2026060911214405500_bib30","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence--inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2026060911214405500_bib31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence--indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026060911214405500_bib32","doi-asserted-by":"crossref","first-page":"e081904","DOI":"10.1136\/bmj-2024-081904","article-title":"Core GRADE 2: choosing the target of certainty rating and assessing imprecision","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"key":"2026060911214405500_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026060911214405500_bib34","author":"McMaster University and Evidence Prime","year":"2025"},{"issue":"5","key":"2026060911214405500_bib35","first-page":"1484","article-title":"Clinical comparation of two kinds of chemotherapy regimen in the treatment of elderly MDS patients with AML transformed by abnormal proliferation of bone marrow","volume":"24","author":"Zhou","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"13","key":"2026060911214405500_bib36","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2022009391","article-title":"Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity","volume":"7","author":"Bazinet","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026060911214405500_bib37","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"2026060911214405500_bib38","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"key":"2026060911214405500_bib39","doi-asserted-by":"crossref","first-page":"106904","DOI":"10.1016\/j.leukres.2022.106904","article-title":"Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA\/venetoclax","volume":"119","author":"Chojecki","year":"2022","journal-title":"Leuk Res"},{"issue":"7","key":"2026060911214405500_bib40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2026060911214405500_bib41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: the impact of co-occurring NPM1 mutations and venetoclax-based treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2026060911214405500_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2026060911214405500_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026060911214405500_bib44","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2026060911214405500_bib45","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"2026060911214405500_bib46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann Hematol"},{"issue":"3","key":"2026060911214405500_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-021-00435-1","article-title":"Mayo Clinic experience with 1123 adults with acute myeloid leukemia","volume":"11","author":"Begna","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026060911214405500_bib48","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.26941","article-title":"Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion","volume":"98","author":"Daver","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2026060911214405500_bib49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41409-023-01977-7","article-title":"Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia","volume":"58","author":"Jamy","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026060911214405500_bib50","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S2152-2650(23)01013-3","article-title":"Characteristics and outcomes of patients with acute myeloid leukemia and DDX41 mutation","volume":"23","author":"Bataller","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026060911214405500_bib51","doi-asserted-by":"crossref","first-page":"2230738","DOI":"10.1080\/16078454.2023.2230738","article-title":"Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center","volume":"28","author":"Lian","year":"2023","journal-title":"Hematol U K"},{"key":"2026060911214405500_bib52","unstructured":"Weng\n              J\n            \n          . Randomized study of ABC-14 regimen compared with \u201c3+7\u201d standard induction therapy or AB-14 for ND AML. ClinicalTrials.gov identifier: NCT06451861. Updated 17 November 2025. Accessed 17 December 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT06451861."},{"key":"2026060911214405500_bib53","unstructured":"Reimann\n              M\n            \n          . Venetoclax plus azacitidine versus intensive chemotherapy for fit patients with newly diagnosed NPM1 mutated AML (VINCENT). ClinicalTrials.gov identifier: NCT05904106. Updated 2 December 2024. Accessed 17 December 2025. https:\/\/clinicaltrials.gov\/study\/NCT05904106."},{"key":"2026060911214405500_bib54","unstructured":"Fathi\n              A\n            \n          . Venetoclax + azacitidine vs. induction chemotherapy in AML. ClinicalTrials.gov identifier: NCT04801797. Updated 14 November 2025. Accessed 17 December 2025. https:\/\/clinicaltrials.gov\/study\/NCT04801797."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4067\/2525484\/blooda_adv-2025-016877-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/4067\/2525484\/blooda_adv-2025-016877-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:22:19Z","timestamp":1781018539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/4067\/566563\/Conventional-therapy-vs-HMA-or-LDAC-with-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016877","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,6,9]]}}}